The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APGE | +106.12% | N/A | N/A | +244% |
| S&P | +17.45% | +75.43% | +11.88% | +50% |
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$406.00K | -434.2% |
| Market Cap | $4.50B | 69.7% |
| Market Cap / Employee | $17.24M | 0.0% |
| Employees | 261 | 33.2% |
| Net Income | -$69,387.00K | -3.2% |
| EBITDA | -$77,650.00K | -2.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $131.55M | -7.2% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.35M | -37.8% |
| Short Term Debt | $3.50M | 8.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.26% | 1.3% |
| Return On Invested Capital | -25.05% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$62,751.00K | 7.3% |
| Operating Free Cash Flow | -$62,689.00K | 7.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.10 | 3.84 | 3.82 | 9.37 | 159.68% |
| Price to Tangible Book Value | 3.10 | 3.84 | 3.82 | 9.37 | 159.68% |
| Enterprise Value to EBITDA | -26.60 | -28.08 | -25.64 | -56.42 | 95.68% |
| Return on Equity | -27.9% | -34.1% | -38.4% | -31.6% | -4.95% |
| Total Debt | $11.82M | $10.85M | $9.85M | $8.85M | -25.20% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
